Vaginal Administration of Metformin in PCOS Patients.
Vaginal Administration of Metformin in PCOS Patients.
Polycystic ovary syndrome is a common cause of irregular periods, poor ovulation and delay in
 achieving pregnancy. Certain drugs may help improve ovarian activity in such women as
 metformin. Oral administration of metformin is accompanied by undesirable side effects. The
 vagina proved to be a good alternative to the oral route for other drugs. Using metformin
 through the vagina and avoidance of such side effects, while maintaining its effectiveness,
 would help women to better tolerate this drug.
PCOS is the most common of all female endocrinopathies affecting 7-10% of women. A variety of
 drugs have been used to help improve follicular dynamics in PCOS patients. Metformin, an
 insulin sensitizer long known for its antidiabetic properties, has been used in PCOS
 patients. One of the major factors affecting compliance are the gastrointestinal side effects
 associated with oral administration of metformin. Knowing that the vagina is a good
 absorptive surface for many drugs, it is postulated that vaginal administration of metformin
 could be a good alternative to the oral route, if it proves effective. Both pharmacokinetic
 and clinical evidences of efficacy are traced for the vaginal route of administration.
Inclusion Criteria:

 -  women with PCOS according to the Rotterdam criteria

 -  age 20-35 years

 -  not to have received any induction of ovulation in the preceding 3 months before
 enrollment

 Exclusion Criteria:

 -  contraindications to metformin

 -  prior surgical management of PCOS